A. Serial change of PHD3 after surgery
V. CONCLUSION
Our findings suggest that serum PHD3 and ESM-1 could serve as novel biomarkers for RCC diagnosis and postsurgical monitoring, providing acceptable diagnostic performance. These serologic biomarkers could help differentiate RCC from benign renal masses. Although our findings should be validated in a larger cohort, serum PHD3 and ESM-1 appear to be suitable for clinical application in diagnosing and monitoring patients with RCC.
20 REFERENCES
1. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
2. Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR. Renal cell cancer stage migration: analysis of the National Cancer Data Base.
Cancer 2008;113:78-83.
3. Ngo TC, Wood CG, Karam JA. Biomarkers of renal cell carcinoma.
Urol Oncol 2014;32:243-51.
4. Schödel J, Grampp S, Maher ER, Moch H, Ratcliffe PJ, Russo P, et al.
Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer.
Eur Urol 2016;69:646-57.
5. Mole DR, Blancher C, Copley R, Pollard PJ, Gleadle JM, Ragoussis J, et al. Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts. J Biol Chem 2009;284:16767-75.
6. Weiss RH, Lin PY. Kidney cancer: identification of novel targets for therapy. Kidney Int 2006;69:224-32.
7. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation:
implications for O2 sensing. Science 2001;292:464-8.
8. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole
21
DR, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001;107:43-54.
9. Jokilehto T, Jaakkola PM. The role of HIF prolyl hydroxylases in tumour growth. J Cell Mol Med 2010;14:758-70.
10. Su Y, Loos M, Giese N, Hines OJ, Diebold I, Görlach A, et al. PHD3 regulates differentiation, tumour growth and angiogenesis in pancreatic cancer. Br J Cancer 2010;103:1571-9.
11. Cui L, Qu J, Dang S, Mao Z, Wang X, Fan X, et al. Prolyl hydroxylase 3 inhibited the tumorigenecity of gastric cancer cells. Mol Carcinog 2014;53:736-43.
12. Tanaka T, Kitamura H, Torigoe T, Hirohashi Y, Sato E, Masumori N, et al. Autoantibody against hypoxia-inducible factor prolyl hydroxylase-3 is a potential serological marker for renal cell carcinoma. Journal of Cancer Research & Clinical Oncology 2011;137:789-94.
13. Sato E, Torigoe T, Hirohashi Y, Kitamura H, Tanaka T, Honma I, et al.
Identification of an immunogenic CTL epitope of HIFPH3 for immunotherapy of renal cell carcinoma. Clin Cancer Res 2008;14:6916-23.
14. Amatschek S, Koenig U, Auer H, Steinlein P, Pacher M, Gruenfelder A, et al. Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. Cancer Res
22 2004;64:844-56.
15. Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C, et al.
Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy.
Biochim Biophys Acta 2006;1765:25-37.
16. Delehedde M, Devenyns L, Maurage CA, Vivès RR. Endocan in cancers: a lesson from a circulating dermatan sulfate proteoglycan. Int J Cell Biol 2013;2013:705027.
17. Bechard D, Meignin V, Scherpereel A, Oudin S, Kervoaze G, Bertheau P, et al. Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies.
J Vasc Res 2000;37:417-25.
18. Lassalle P, Molet S, Janin A, Heyden JV, Tavernier J, Fiers W, et al.
ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem 1996;271:20458-64.
19. Rennel E, Mellberg S, Dimberg A, Petersson L, Botling J, Ameur A, et al. Endocan is a VEGF-A and PI3K regulated gene with increased expression in human renal cancer. Exp Cell Res 2007;313:1285-94.
20. Leroy X, Aubert S, Zini L, Franquet H, Kervoaze G, Villers A, et al.
Vascular endocan (ESM-1) is markedly overexpressed in clear cell renal cell carcinoma. Histopathology 2010;56:180-7.
21. Ambani SN, Morgan TM, Montgomery JS, Gadzinski AJ, Jacobs BL,
23
Hawken S, et al. Predictors of Delayed Intervention for Patients on Active Surveillance for Small Renal Masses: Does Renal Mass Biopsy Influence Our Decision? Urology: The Gold Journal 2016;98:88-96.
22. Morrissey J, Mellnick VM, Luo J, Siegel MJ, Figenshau RS, Bhayani S, et al. Evaluation of Urine Aquaporin-1 and Perilipin-2 Concentrations as Biomarkers to Screen for Renal Cell Carcinoma: A Prospective Cohort Study. JAMA Oncol 2015;1:204-12.
23. Eichelberg C, Junker K, Ljungberg B, Moch H. Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol 2009;55:851-63.
24. Stillebroer AB, Mulders PF, Boerman OC, Oyen WJ, Oosterwijk E.
Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol 2010;58:75-83.
25. Divgi CR, Uzzo RG, Gatsonis C, Bartz R, Treutner S, Yu JQ, et al.
Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin
24 Rev Mol Cell Biol 2004;5:343-54.
28. Xue J, Li X, Jiao S, Wei Y, Wu G, Fang J. Prolyl hydroxylase-3 is down-regulated in colorectal cancer cells and inhibits IKKbeta independent of hydroxylase activity. Gastroenterology 2010;138:606-15.
29. Fox SB, Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, et al.
The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen. Breast Cancer Res 2011;13:R16-R.
30. Gossage L, Zaitoun A, Fareed KR, Turley H, Aloysius M, Lobo DN, et al. Expression of key hypoxia sensing prolyl-hydroxylases PHD1, -2 and -3 in pancreaticobiliary cancer. Histopathology 2010;56:908-20.
31. Tanaka T, Torigoe T, Hirohashi Y, Sato E, Honma I, Kitamura H, et al.
Hypoxia-inducible factor (HIF)-independent expression mechanism and novel function of HIF prolyl hydroxylase-3 in renal cell carcinoma.
Journal of Cancer Research & Clinical Oncology 2014;140:503-13.
32. Ozaki K, Toshikuni N, George J, Minato T, Matsue Y, Arisawa T, et al.
Serum endocan as a novel prognostic biomarker in patients with hepatocellular carcinoma. J Cancer 2014;5:221-30.
33. Xu Z, Zhang S, Zhou Q, Wang Y, Xia R. Endocan, a potential prognostic and diagnostic biomarker of acute leukemia. Mol Cell
25 Biochem 2014;395:117-23.
34. Ji NY, Kim Y, Jang YJ, Kang YH, Lee CI, Yeom YI, et al. Identification of endothelial cell-specific molecule-1 as a potential serum marker for colorectal cancer. Cancer Sci 2010;101:2248-53.
35. Maurage C, Adam E, Minéo J, Sarrazin S, Debunne M, Siminski R, et al. Endocan expression and localization in human glioblastomas. J Neuropathol Exp Neurol 2009;68:633-41.
36. Kim JH, Park MY, Kim CN, Kang HB, Kim KD. Expression of endothelial cell-specific molecule-1 regulated by hypoxia inducible factor-1α in human colon carcinoma: impact of ESM-1 on prognosis and its correlation with clinicopathological features. Oncol Rep 2012;28:1701-8.
37. Chen LY, Liu X, Wang SL, Qin CY. Over-expression of the Endocan gene in endothelial cells from hepatocellular carcinoma is associated with angiogenesis and tumour invasion. J Int Med Res 2010;38:498-510.
38. Kaelin WG. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 2007;13:680s-4s.
39. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005;7:77-85.
26
40. Vetterlein MW, Jindal T, Becker A, Regier M, Kluth LA, Tilki D, et al.
Small renal masses in the elderly: Contemporary treatment approaches and comparative oncological outcomes of nonsurgical and surgical strategies. Investigative and Clinical Urology 2016;57:231-9.
27
28
대조군의 PHD3, ESM-1 수치가 비교되었고, 신세포암에서는 술 후 수치의 변화를 비교하였다. PHD3와 ESM-1의 진단 성능을 평가하기 위해 Area Under Curve (AUC)를 계산하였다.
결과: 혈청 PHD3와 ESM-1은 신세포암 환자에서 대조군에 비하여 통계적으로 유의하게 높게 관찰되었다 (PHD3; 0.79±0.17 ng/ml vs. 0.73±0.09 ng/ml, p=0.023) (ESM-1; 0.59±0.07 ng/ml vs.
0.53±0.09 ng/ml, p<0.001). PHD3와 ESM-1의 AUC는 각각 0.668과 0.684였다. 종양의 크기가 2 cm이상인 환자들만을 분석하였을 때 PHD3와 ESM-1의 AUC는 각각 0.709와 0.730이었다. 술 후 변화를 확인하였을 때 신세포암 환자에서 술 후 1개월 째 혈청 PHD3와 ESM-1은 유의하게 감소하였다 (PHD3; p=0.050, ESM-1;
p=0.047).
결론: 혈청 PHD3와 ESM-1은 새로운 신세포암의 진단 바이오마커이며 적절한 진단 성능을 보여주었다. 또한 PHD3와 ESM-1은 신세포암에서 수술 후 감시 바이오마커로서 효용성이 있을 것으로 보인다.
핵심되는 말 : 신세포암; 바이오마커; 조기진단
29